- Home
- KLIC vs NNNN Comparison
KLIC vs NNNN Comparison
Compare KLIC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLIC
- NNNN
- Stock Information
- Founded
- KLIC 1951
- NNNN 2021
- Country
- KLIC United States
- NNNN Germany
- Employees
- KLIC N/A
- NNNN N/A
- Industry
- KLIC Semiconductors
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- KLIC Technology
- NNNN Health Care
- Exchange
- KLIC Nasdaq
- NNNN Nasdaq
- Market Cap
- KLIC 2.0B
- NNNN 2.2B
- IPO Year
- KLIC N/A
- NNNN 2025
- Fundamental
- Price
- KLIC $35.79
- NNNN $27.36
- Analyst Decision
- KLIC Buy
- NNNN
- Analyst Count
- KLIC 4
- NNNN 0
- Target Price
- KLIC $45.00
- NNNN N/A
- AVG Volume (30 Days)
- KLIC 368.0K
- NNNN 39.8K
- Earning Date
- KLIC 11-19-2025
- NNNN 04-28-2026
- Dividend Yield
- KLIC 2.29%
- NNNN N/A
- EPS Growth
- KLIC N/A
- NNNN N/A
- EPS
- KLIC 0.11
- NNNN 0.06
- Revenue
- KLIC $657,842,000.00
- NNNN $8,185,146.00
- Revenue This Year
- KLIC N/A
- NNNN N/A
- Revenue Next Year
- KLIC $18.61
- NNNN N/A
- P/E Ratio
- KLIC $325.32
- NNNN $503.50
- Revenue Growth
- KLIC N/A
- NNNN 21.95
- 52 Week Low
- KLIC $26.63
- NNNN $5.18
- 52 Week High
- KLIC $52.08
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- KLIC 34.59
- NNNN 54.26
- Support Level
- KLIC $38.32
- NNNN $12.93
- Resistance Level
- KLIC $39.41
- NNNN $25.20
- Average True Range (ATR)
- KLIC 1.13
- NNNN 4.99
- MACD
- KLIC -0.41
- NNNN 1.61
- Stochastic Oscillator
- KLIC 13.07
- NNNN 73.40
About KLIC Kulicke and Soffa Industries Inc.
Kulicke & Soffa Industries Inc is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments which includes Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.